Literature DB >> 9390204

Utility of hyaluronic acid in pleural fluid for differential diagnosis of pleural effusions: likelihood ratios for malignant mesothelioma.

S Atagi1, M Ogawara, M Kawahara, M Sakatani, K Furuse, E Ueda, S Yamamoto.   

Abstract

The level of hyaluronic acid (HA) was determined in the pleural fluid of 99 patients, including 19 with malignant mesothelioma, 27 with lung cancer, 1 with breast cancer, 1 with mediastinal tumor and 51 with non-malignant diseases. With a cut-off level at 100 micrograms/ml, the pleural fluid concentration of HA was high in 36.8% of patients (7 of 19) with malignant mesothelioma and 1.3% of patients (1 of 80) with lung cancer and other malignant and non-malignant diseases. The mean concentration of pleural fluid HA was significantly higher in patients with mesothelioma than in those with lung cancer and other malignant and non-malignant diseases. The pre-test probability of MM was 5.9% in this series. The LRs for > or = 100, 50-99 and < or = 49 micrograms/ml are 28.3, 3.3 and 0.5, respectively; these put the post-test probabilities at 64, 17 and 3%, respectively. Indeed, in cases of uncommon disease such as MM, the post-test probability is low even if the cut-off level of HA is > or = 100 micrograms/ml. The discrimination between malignant mesothelioma and lung cancer needs special attention. In these two diseases, the LRs of MM for pleural fluid CEA > 30, 10-30 and < 10 ng/ml were 0.2, 1.9 and 2.4, respectively. The pre-test probability of MM for HA > or = or 100 micrograms/ml is 64%. Furthermore, because the LR for CEA is < 10 ng/ml, the post-test probability is 81%. When the combination of two markers is considered, the high level of HA and the low level of CEA may be useful for the differential diagnosis of MM from pleuritis carcinomatosa.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9390204     DOI: 10.1093/jjco/27.5.293

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  7 in total

1.  Cytological diagnosis of malignant mesothelioma--improvement by additional analysis of hyaluronic acid in pleural effusions.

Authors:  L Welker; M Müller; O Holz; E Vollmer; H Magnussen; R A Jörres
Journal:  Virchows Arch       Date:  2007-02-15       Impact factor: 4.064

Review 2.  Biomarkers for malignant pleural mesothelioma: current status.

Authors:  Laurent Greillier; Paul Baas; John J Welch; Baktiar Hasan; Alexandre Passioukov
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

3.  Tissue hyaluronan expression, as reflected in the sputum of lung cancer patients, is an indicator of malignancy.

Authors:  M P Rangel; V K de Sá; V Martins; J R M Martins; E R Parra; A Mendes; P C Andrade; R M Reis; A Longatto-Filho; C Z Oliveira; T Takagaki; D M Carraro; H B Nader; V L Capelozzi
Journal:  Braz J Med Biol Res       Date:  2015-05-08       Impact factor: 2.590

Review 4.  CD44 and its ligand hyaluronan as potential biomarkers in malignant pleural mesothelioma: evidence and perspectives.

Authors:  Lourdes Cortes-Dericks; Ralph Alexander Schmid
Journal:  Respir Res       Date:  2017-04-12

5.  Diagnostic method for malignant pleural effusion distinguishing malignant mesothelioma from lung cancer using pleural carcinoembryonic antigen and hyaluronic acid levels.

Authors:  Takeshi Saraya; Kosuke Ohkuma; Masachika Fujiwara; Haruyuki Ishii
Journal:  Medicine (Baltimore)       Date:  2022-01-07       Impact factor: 1.889

6.  Biomarkers for early detection of malignant mesothelioma: diagnostic and therapeutic application.

Authors:  Marco Tomasetti; Lory Santarelli
Journal:  Cancers (Basel)       Date:  2010-04-14       Impact factor: 6.639

7.  Multiplex Soluble Biomarker Analysis from Pleural Effusion.

Authors:  Joman Javadi; Katalin Dobra; Anders Hjerpe
Journal:  Biomolecules       Date:  2020-07-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.